Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 4Specimen Handling 3Magnetic Resonance Spectroscopy 3tislelizumab 2aflibercept 2Surveys and Questionnaires 2Radiotherapy 2Gene Expression Profiling 2Fentanyl 2Docetaxel 2Diet Therapy 2Blood Specimen Collection 2Biopsy 2trastuzumab deruxtecan 1toripalimab 1spartalizumab 1sargramostim 1rucaparib 1pegfilgrastim 1pazopanib 1olaparib 1milademetan 1entinostat 1durvalumab 1ciforadenant 1ceralasertib 1cemiplimab 1avelumab 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × ciforadenant × Sarcoma × Clear all
NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

Phase 1 Completed
117 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡